Sapanisertib

Generic Name: Sapanisertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅N_₇O

CAS Number: 1224844-38-5

Unique Ingredient Identifier: JGH0DF1U03

Background: Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Sapanisertib
Drug: Serabelisib
Drug: Paclitaxel

First Posted Date: 2024-06-17

Last Posted Date: 2024-12-18

Lead Sponsor: Faeth Therapeutics

Target Recruit Count: 40

Registration Number: NCT06463028

Locations: 🇺🇸
Women's Cancer Care Associates, LLC, Albany, New York, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-30

Last Posted Date: 2024-11-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT06390865

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Multiple Myeloma
Advanced Lymphoma
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-26

Last Posted Date: 2024-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06385496

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: NFE2L2 Gene Mutation
Squamous Non-Small Cell Neoplasm of Lung
Non-Small Cell Lung Cancer
Squamous Non-small-cell Lung Cancer

Interventions: Drug: sapanisertib

First Posted Date: 2022-03-11

Last Posted Date: 2023-04-04

Lead Sponsor: Calithera Biosciences, Inc

Target Recruit Count: 7

Registration Number: NCT05275673

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center - Thoracic, New York, New York, United States
🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa, California, United States

and more 10 locations

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Phase 1

Withdrawn

Conditions: Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8

Interventions: Biological: Nivolumab
Drug: Sapanisertib

First Posted Date: 2021-08-26

Last Posted Date: 2022-05-27

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05022394

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8

Interventions: Drug: Alisertib
Drug: Osimertinib
Drug: Sapanisertib

First Posted Date: 2020-07-21

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT04479306

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2

Withdrawn

Conditions: Lung Squamous Cell Carcinoma
Recurrent Lung Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions: Drug: Dexamethasone
Drug: Docetaxel
Biological: Ramucirumab
Drug: Sapanisertib

First Posted Date: 2020-02-13

Last Posted Date: 2020-11-20

Lead Sponsor: SWOG Cancer Research Network

Registration Number: NCT04267913

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Brain
Stage IV Lung Cancer AJCC v8
Leptomeningeal Neoplasm
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma

Interventions: Drug: Sapanisertib
Drug: Telaglenastat Hydrochloride

First Posted Date: 2020-01-31

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT04250545

Locations: 🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 4 locations

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Phase 1

Completed

Conditions: Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Sapanisertib

First Posted Date: 2018-02-13

Last Posted Date: 2022-06-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03430882

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2

Active, not recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Bladder Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Metastatic Transitional Cell Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions: Drug: Sapanisertib

First Posted Date: 2017-02-08

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT03047213

Locations: 🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy